Latest Breaking News On - Prnewswire fusion pharmaceuticals inc - Page 9 : comparemela.com

Fusion Pharmaceuticals and BWXT Medical Announce Actinium-225 Partnership to Scale Supply for Developing Targeted Alpha Therapies

Fusion Pharmaceuticals and BWXT Medical Announce Actinium-225 Partnership to Scale Supply for Developing Targeted Alpha Therapies
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Amanda crayseniorJohn valliantJonathan cirtainFusion pharmaceuticals incMcmaster universityTechnologies incFusion pharmaceuticalsPrnewswire fusion pharmaceuticals incInvestor relations corporate communicationsChief executive officer john valliantChief executive officer jonathan cirtainResponse inhibitorsOntario based mcmaster universityGood manufacturing practiceDefense news topPrivate securities litigation reform act

Fusion Pharmaceuticals and BWXT Medical Announce Actinium-225 Partnership to Scale Supply for Developing Targeted Alpha Therapies

/PRNewswire/ Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), and BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc. (NYSE: BWXT), today announced that.

John valliantJonathan cirtainAmanda crayFusion pharmaceuticals incMcmaster universityTechnologies incFusion pharmaceuticalsPrnewswire fusion pharmaceuticals incInvestor relations corporate communicationsChief executive officer john valliantChief executive officer jonathan cirtainResponse inhibitorsOntario based mcmaster universityGood manufacturing practiceDefense news topPrivate securities litigation reform act

Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as.

United statesAmanda crayFusion pharmaceuticals incNiowave incCompany board of directorsFusion pharmaceuticalsPrnewswire fusion pharmaceuticals incInvestor relations corporate communicationsNasdaq listing ruleRepair inhibitorsSenior directorInvestor relationsCorporate communicationsFusion pharmaceuticals inc

Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as.

United statesAmanda crayFusion pharmaceuticals incNiowave incCompany board of directorsFusion pharmaceuticalsPrnewswire fusion pharmaceuticals incInvestor relations corporate communicationsNasdaq listing ruleRepair inhibitorsSenior directorInvestor relationsCorporate communications

Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as.

United statesAmanda crayFusion pharmaceuticals incNiowave incCompany board of directorsFusion pharmaceuticalsPrnewswire fusion pharmaceuticals incInvestor relations corporate communicationsNasdaq listing ruleRepair inhibitorsSenior directorInvestor relationsCorporate communicationsFusion pharmaceuticals incHealth care amp hospitalsMedical pharmaceuticals